| Nov 13 |
Viracta Therapeutics GAAP EPS of -$0.27 misses by $0.03
|
| Nov 13 |
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 6 |
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
|
| Sep 3 |
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 8 |
Why Digital Turbine Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
|
| May 17 |
Viracta Therapeutics Announces New Employment Inducement Grants
|
